Dutch Biotech Innovation Delegation Concludes Successful Visit to China

On March 16, 2026, the Dutch Biotech Innovation Delegation’s visit to China came to a successful close. Under the theme “Deepening Exchange and Cooperation in Biotech between China and the Netherlands,” the visit brought together representatives from top Dutch research institutions, biotech companies, and relevant policy-making bodies, who engaged in in-depth discussions with multiple Chinese biotech firms and research institutes.

Discussing Frontiers, Seeking Common Development

During the exchanges, the two sides held a series of thematic seminars on core topics such as synthetic biology, advanced manufacturing, clinical trial systems, and pharmaceutical innovation. The Dutch delegation shared their cutting-edge explorations in cell and gene therapy, microfluidics, and bio-intelligent manufacturing, while Chinese companies including Canton Biologics presented their practical achievements in areas such as high-expression cell line development. Both sides conducted thorough discussions on technological innovation and industrial translation. The exchanges enhanced mutual understanding of each other’s research systems and industrial ecosystems, laying a good foundation for future cooperation in joint R&D, technology transfer, and talent development.

During the dialogue, representatives of Canton Biologics introduced the company’s development journey and technical strengths. Since its founding on Guangzhou Bio Island, Canton Biologics has, over nearly a decade, established four R&D and manufacturing sites in China and Germany, growing into a medium-sized biologics CDMO with international service capabilities. Leveraging its synergistic presence in both China and Germany and long‑term accumulation of China‑Europe cooperation, Canton Biologics has built differentiated advantages in core technologies such as cell line development, plasmid construction, and medium optimization, establishing an efficient and stable technology platform. With these capabilities, the company provides one‑stop services from cell line construction to pilot‑scale production for both Chinese and international clients, successfully supporting numerous projects to advance to clinical stages and beyond, continuously empowering clients’ drug development processes.

As a major innovation hub in European life sciences, the Netherlands has deep expertise in cell and gene therapy, biomanufacturing, and clinical trial systems. The successful conclusion of this China‑Netherlands Biotech Innovation Exchange adds a new chapter to bilateral cooperation in biotechnology. The Netherlands’ top‑tier research strength and open innovation ecosystem form an excellent complement to the Greater Bay Area’s robust industrial layout, abundant clinical resources, and strong translational capabilities.

Though the exchange lasted only one day, the dialogue itself is the starting point. As one of the participants in this exchange, Canton Biologics will continue to uphold an open and cooperative attitude, maintain communication with its Dutch counterparts, and explore further possibilities in technology transfer and industrial practice. We look forward to this cross‑continental dialogue bearing tangible fruit in the future.